MedTrace Logo

GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification

NCT03618667 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-05-12

No results posted yet for this study

Summary

This study is a phase 2 trial of GC1118, an EGFR monoclonal antibody, for recurrent glioblastoma patients who were treated with standard concurrent chemoradiation.

Conditions

  • Glioblastoma, Adult
  • EGFR Amplification

Interventions

DRUG

GC1118

GC1118 (4mg/kg) will be administered by IV infusion once per week for 4 weeks(28-day cycles) up to 6 cycles, or till progression or uncontrolled toxicity.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • sehoon lee, professor · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-22
Primary Completion
2018-09-08
Completion
2022-04-28

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03618667 on ClinicalTrials.gov